SuPAR in major depression: Association with 26 weeks antidepressant response and 10-year depression outcomes

T H Haupt; B Elfving; J Eugen-Olsen; O Mors; O Köhler-Forsberg

doi:10.1016/j.bbih.2023.100685

SuPAR in major depression: Association with 26 weeks antidepressant response and 10-year depression outcomes

Brain Behav Immun Health. 2023 Sep 7:33:100685. doi: 10.1016/j.bbih.2023.100685. eCollection 2023 Nov.

Authors

T H Haupt^{1

2}, B Elfving^{3

4}, J Eugen-Olsen¹, O Mors^{4

5}, O Köhler-Forsberg^{4

5}

Affiliations

¹ Department of Clinical Research, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.
² Psychiatric Center Ballerup, Ballerup, Denmark.
³ Translational Neuropsychiatry Unit (TNU), Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
⁴ Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
⁵ Psychosis Research Unit, Aarhus University Hospital - Psychiatry, Aarhus, Denmark.

Abstract

Introduction: Inflammation has been associated with depression and differential antidepressant (AD) treatment response. Soluble urokinase plasminogen activator receptor (suPAR) is a novel measure of chronic inflammation. We investigated whether suPAR is associated with depression severity and AD response.

Methods: We included 90 patients with major depressive disorder (MDD) who participated in a part-randomized clinical trial of 26 weeks of treatment with escitalopram or nortriptyline. suPAR levels were measured in serum samples collected at baseline and after 8, 12 and 26 weeks. Mixed effects models for the association between suPAR levels and AD response were performed. By merging with Danish nationwide registers, we included information on psychiatric hospital contacts during ten years after the GENDEP trial. Cox regression analyses calculated the hazard rate ratios between suPAR levels and subsequent hospitalizations.

Results: At baseline, higher suPAR levels were not associated with overall depression severity but with greater severity of neurovegetative depressive symptoms, specifically appetite and weight changes. 57 (63.3%) patients responded positively to treatment. Among 57 (63.3%) patients who achieved response, those who responded had significantly higher baseline suPAR levels levels, and response was associated with a significant decrease in suPAR during AD treatment. Remitters decreased from 3.1 ng/ml at baseline to 2.8 ng/ml after 26 weeks (p = 0.003) and responders from 3.0 to 2.8 ng/ml (p = 0.02), whereas non-remitters and non-responders showed unchanged suPAR levels. We found no correlation between a change in suPAR and a change in MADRS, but a lowering of suPAR correlated with a decrease in neurovegetative symptoms. We found no association between suPAR levels and 10-year risk for hospitalizations.

Discussion: The present study suggests that an elevated level of chronic inflammation, measured as the suPAR level, is associated with better response to AD treatment.

Keywords: Clinical study; Depression; Immunology; Inflammation; Psychiatry; Treatment.